[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492133":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":39,"collaborators":41,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":7,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"University Hospital, Ghent","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Piet Pattyn, MD, PhD","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+32 9 332 1295","piet.pattyn@ugent.be",{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},"Annouck Philippron, MD","+32 9 332 1531","annouck.philippron@ugent.be",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"University hospital Ghent","RECRUITING","Ghent","Oost-Vlaanderen","9000","Belgium","BE",{"type":31,"coordinates":32},"Point",[33,34],3.71667,51.05,{"lat":34,"lon":33},[37,38],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[42],{"name":43,"class":6},"Universitaire Ziekenhuizen KU Leuven","100492133","barretts-esophagus-and-esophageal-adenocarcinoma-searching-for-reliable-diagnostic-rna-plasma-based-biomarkers-100492133",false,"NCT05688176","Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers","Liquid Biopsies in Esophageal Adenocarcinoma: Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers","Inclusion Criteria:\n\n* Barrett's Esophagus with length \\> 3cm OR esophageal adenocarcinoma histologically proven\n* Adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent\n* Age over 18 years\n* No other concurrent malignant disease\n* No inclusion in other clinical trials interfering with the study protocol\n* No concurrent chronic systemic immune or hormone therapy, except neoadjuvant chemotherapy\n* Absence of any severe organ insufficiency\n* No pregnancy or breast feeding\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breast feeding\n* Active bacterial, viral or fungal infection\n* Parenchymal liver disease (any stage cirrhosis)\n* High risk of bleeding during biopsy (anticoagulants, esophageal varices)\n* Esophageal squamous cell carcinoma\n* Helicobacter pylori positive at the time of biopsy sampling\n* Radiofrequency ablation of the oesophagus\n* Psychiatric pathology capable of affecting comprehension and judgement faculty",true,"ALL","18 Years",{"count":55,"type":56},100,"ESTIMATED","OBSERVATIONAL","This study is designed to perform a explorative search of the transcriptome to detect new circulating diagnostic sensitive and specific biomarkers in patients with Barrett's esophagus or esophageal adenocarcinoma.",[60],"Esophageal Neoplasms",[60,62,63],"Liquid biopsy","Transcriptome","2024-07-16",{"date":66,"type":67},"2024-07-17","ACTUAL",{"date":69,"type":7},"2016-06",{"date":71,"type":56},"2027-01-31",{"name":5,"class":6},1]